0.9% SODIUM CHLORIDE INJECTION 500ML — DIN 02395150

What is 0.9% SODIUM CHLORIDE INJECTION?

0.9% SODIUM CHLORIDE INJECTION 500ML contains SODIUM CHLORIDE 900 MG. It is listed in the Health Canada Drug Product Database under DIN 02395150, held by FRESENIUS KABI CANADA LTD, supplied as Solution for Intravenous administration. Health Canada currently lists it as marketed, status dated 24-Feb-2023. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

What is 0.9% SODIUM CHLORIDE INJECTION used for?

0.9% Sodium Chloride Injection is indicated as a source of water and electrolytes. It can be used as a vehicle or diluent for compatible products for parenteral administration. It is also indicated for use as a priming solution in hemodialysis procedures.

Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.

How is it administered?

As directed by a physician, dosage, rate, and duration of administration are to be individualized and depend upon the indication for use, the patient's age, weight, clinical condition, and concomitant treatment, and on the patient's clinical and laboratory response to treatment. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Do not administer unless the solution is clear and seals are intact. 0.9% Sodium Chloride Injection freeflex® / freeflex® plastic containers are intended for intravenous administration using sterile equipment. It is recommended that intravenous administration apparatus be replaced at least once every 24 hours. Additives may be incompatible with 0.9% Sodium Chloride Injection. Compatibility of additives with 0.9% Sodium Chloride Injection must be assessed before addition. Additives known, determined or suspected to be incompatible should not be used. Before adding a substance or medication, verify that it is soluble and/or stable in water and that the pH of 0.9% Sodium Chloride Injection is appropriate. The instructions for use of the medication to be added and other relevant literature must be consulted. When introducing additives to 0.9% Sodium Chloride Injection, aseptic technique must be used. After addition, check for a possible color change and/or the appearance of precipitates, insoluble complexes or crystals. Mix the solution thoroughly when additives have been introduced. Do not store solutions containing additives. When other electrolytes or medicines are added to this solution, the dosage and the infusion rate will also be dictated by the dose regimen of the additions. For single use only. Discard any unused portion.

Included because it drives pack selection and wastage. Consult the monograph.

Contraindications

0.9% Sodium Chloride Injection is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation or component of the container. For a complete listing, see the Dosage Form, Composition and Packaging section of the Prescribing Information. 0.9% Sodium Chloride Injection is contraindicated in situations where administration of sodium or chloride could be clinically detrimental.

Warnings and precautions

0.9% Sodium Chloride Injection should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency and in clinical states in which there exists edema with sodium retention. In patients with diminished renal function, administration of 0.9% Sodium Chloride Injection may result in sodium retention. Intravenous administration of 0.9% Sodium Chloride Injection may cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states, clinically relevant electrolyte disturbances, acid-base imbalance and/or central and peripheral edema. The risk of fluid and/or solute overload is directly proportional to the volume of the product intravenously administrated. Excessive administration of potassium free solutions may result in significant hypokalemia. Hypersensitivity/infusion reactions, including hypotension, pyrexia, tremor, chills, urticaria, rash, and pruritus, have been reported with 0.9% Sodium Chloride Injection. Stop the infusion immediately if signs or symptoms of hypersensitivity/infusion reactions develop. Appropriate therapeutic countermeasures must be instituted as clinically indicated. Depending on the volume and rate of infusion, intravenous administration of 0.9% Sodium Chloride Injection can cause fluid and/or solute overload resulting in overhydration/hypervolemia and, for example, congested states, including central and peripheral edema. Clinically relevant electrolyte disturbances and acid-base imbalance. In general, the risk of fluid/solute overload causing congested states and/or electrolyte disturbances is directly proportional to the volume of the products intravenously administrated. Do not connect flexible plastic containers of intravenous solutions in series connections. Such use could result in air embolism due to possible residual air being drawn from one container before administration of the fluid from a secondary container is completed. Pressurizing intravenous solutions contained in flexible plastic containers to increase flow rates can result in air embolism if the residual air in the container is not fully evacuated prior to administration. Use of a vented intravenous administration set with the vent in the open position could result in air embolism. Vented intravenous administration sets with the vent in the open position should not be used with flexible plastic containers.